Award Data

SummaryThe parent Commercialization Readiness Program grant was to conduct studies necessary to support regulatory submissions relating to pre-clinical development of Cenna’s peptide drug candidate mP8. mP8 is being developed as a new, first-in-class peptide drug for the treatment of Alzheimer’s disease. The funded grant builds on the substantial progress made under the previously funded SBIR ...

Project Summary Otitis media (infection of the middle ear space) is one of the most common diseases of childhood. Myringotomy with tympanostomy tube (TT) insertion is the most common operation performed on children in the United States. Otorrhea is the most common complication following tube insertion and can occur in up to 17% of ears receiving TT and is often associated with active infection. Cu ...

Project Summary / Abstract A variety of hazardous compounds continue to pose serious and widespread risks to public health and safety in the United States. Organic compounds, in particular, such as chlorinated solvents, hydrocarbons, disinfection byproducts, pesticides, polyaromatic hydrocarbons (PAHs), polychlorinated biphenyls (PCBs), and other xenobiotic (not naturally occurring) organic chemic ...

This Fast Track Phase I-II SBIR addresses the NHGRI Special Interest Topic C: “Genomics tools ranging from new instruments to sophisticated molecular biology kits”. The recent discoveries of methylomes of reversibly methylated mRNA and early indications of the functional role these play in cellular function and disease, and the introduction of RNA immunoprecipitation sequencing (RIP-Seq) deriv ...

ABSTRACT Diabetes mellitus (DM) is caused by inadequate insulin secretion or an inability to respond appropriately to secreted insulin, which leads to chronic elevated blood sugar levels (hyperglycemia). An estimated 171 million people worldwide have DM, and the prevalence of DM will more than double over the next 2 decades. Diabetic patients have increased rates, severity, and complexity of ather ...

ABSTRACT Systemic administration of small molecule therapeutics to treat disease can be ineffective, and even hazardous, because the drugs distribute widely in the body. This lack of site-specificity means large systemic doses are needed to achieve effective concentrations in the diseased tissues, but these high doses often result in non- specific toxicity. Roughly 1 in 20 hospitalized patients ex ...

The GenNext Phase II SBIR submssion entitled “FoxWare™, an Advanced Data Analysis Package for Hydroxyl Radical Foot-printing Higher Order Structural Analysis” is responsive to the ackowledged need for new and improved tools for higher order structural analysis (HOS) of biopharmaceuticals. Biopharmaceuticals are complex, heterogeneous mixtures of 3-dimensional biomolecules, whose safety and e ...

Need. In the US, 40 million patients with hypertension (HTN) have their blood pressure (BP) uncontrolled. BP above clinical Target even for a few months increases the risk for stroke (35-40%), heart failure (HF) (up to 64%), myocardial infarction (MI) (15-25%). Physician-nurse-pharmacist resource-intensive demonstrations in achieving andamp; maintaining BP Target have shown promising results, but ...

Project Summary Half of new HIV infections occur in women as a result of unprotected vaginal intercourse with an infected partner. The cervicovaginal mucosa is the primary portal of entry for HIV in women. Women often cannot protect themselves due to imbalances in sexual relationships. The long-term goal of this project is to develop a safe and effective product to prevent HIV acquisition in women ...

Abstract PuraCath’s goal with the Phase II SBIR is to develop an FDA-approved therapeutic system for disinfection of a needleless connector (NC) for Peripherally Inserted Central Catheters (PICC) that reduces the risk of intraluminal colonization as a source of catheter-related blood stream infections (CRBSI). More specifically, it utilizes Ultraviolet (UV) light to eliminate microbes and biofil ...